Founded in 2017 and headquartered in Nanjing, Nanjing Delova Biotech Co., Ltd. is a biotechnology company focused on the development of non-addictive new drugs for pain management. Guided by unmet clinical needs in the global pain market, the company aims to provide patients with non-opioid, long-acting, and potent pain management products, using scientific innovation to improve human health and quality of life. Delova has built a full-process team covering new drug research, development, and commercialization. Nearly 70% of the team holds master's or doctoral degrees, with extensive experience in project initiation, long-acting formulation research, quality research, preclinical evaluation, clinical research, regulatory submissions, BD collaboration, and commercialization. The company has also developed a high-barrier, proprietary platform for long-acting extended-release injectable formulations, capable of providing controlled release from days to weeks or months.

Emphasizing a global market strategy, Delova has the ability to conduct synchronous R&D and regulatory submissions in China and the U.S. The company's product series has the potential to reach a multi-billion RMB market once launched. In April 2025, Delova's independently developed new drug, Putanning®/QAMZOVA™, was successfully approved and launched in both China and the U.S., becoming the first analgesic new drug in China to receive FDA approval.